查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美心臟标记市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按产品类型、生物标记类型、适应症、最终用户和国家/地区
市场调查报告书
商品编码
1498570

北美心臟标记市场规模和预测、全球和区域份额、趋势和成长机会分析报告范围：按产品类型、生物标记类型、适应症、最终用户和国家/地区

North America Cardiac Markers Market Size and Forecast, Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Biomarker Type, Indication, End User, and Country
出版日期: | 出版商: The Insight Partners | 英文 106 Pages | 订单完成后即时交付

价格

全球北美心臟标记市场预计将从 2023 年的 11.7 亿美元增至 2031 年的 28.7 亿美元。

本报告中提出的北美心臟标记市场预测可以帮助该市场的利害关係人规划其成长策略。心血管疾病盛行率的上升和对即时心臟检测试剂盒需求的激增是推动北美心臟标记市场成长的关键因素。

使用外泌体作为 CVD 生物标记的持续研究

缺氧显着影响外泌体货物并产生各种蛋白质和 miRNA，这些蛋白质和 miRNA 透过不同的讯号路径指示 CVD 的血管生成、生长和进展。外泌体引起了研究人员的关注，因为它们与生理和病理条件下的细胞间通讯有关。上调的外泌体 miRNA miR-133a、miR-208a、miR-1、miR-499-5p 和 miR-30a 已被指定用于急性心肌梗塞 (AMI) 的及时诊断。此外，衍生的外泌体，即 miR-192、miR-146a、miR-194 和 miR-92b-5p 被认为是 HF 的潜在生物标记。

  • 表 1. 外泌体作为 CVD 生物标记

生物标记疾病功能

miRNA-126、miRNA-223 和 miRNA-320b 急性心肌梗塞 血小板活化和血栓形成、内皮损伤、心肌细胞凋亡和纤维母细胞增殖

miRNA-1、miRNA-21a/b 和 miRNA-29b 急性心肌梗塞 心肌细胞凋亡、纤维母细胞增生和心臟肥大

miRNA-208a 急性心肌梗塞 心臟肥大与电传导

miRNA-499 急性心肌梗塞 心肌细胞凋亡

miRNA-486 急性心肌梗塞 心肌细胞凋亡（保护性）

miRNA-223-5p 急性心肌梗塞、动脉粥状硬化和心臟衰竭 细胞增殖、迁移、凋亡和极化；心肌细胞肥大；和电传导

miRNA-941 急性冠状动脉综合症 细胞增生和炎症

miRNA-216a 和 miRNA-451 冠状动脉疾病 内皮损伤和单核细胞募集

miRNA-223-3p、miRNA-122-5p 和 miRNA-93-5p 冠状动脉疾病 发炎、迁移和凋亡、心肌细胞肥大、电传导和心肌细胞凋亡

miRNA-142-3p、miRNA-17-5p 和 miRNA-126 急性心肌梗塞和冠状动脉疾病发炎；心肌细胞肥大；以及细胞增殖、迁移和凋亡

miRNA-133a 冠状动脉疾病 细胞增生和分化、心臟肥大和电传导（心律不整）

Serpin G1、Serpin F2 和 Cystatin C CD14 心臟衰竭和急性冠状动脉综合征 发炎、肾功能下降、纤溶下降和血栓形成过程

资料来源：艾伦出版社

在冠状动脉疾病（CAD）患者中，上调的外泌体蛋白（包括纤维蛋白原β/γ链、α-1-抗胰凝乳蛋白酶和间α-胰蛋白酶抑制剂重链）被评估为推定的蛋白质生物标记。外泌体透过多种细胞间通讯机制在 CVD 发病机制中的功能正在获得显着认知。近年来进行的几项研究提供的证据支持外泌体与正常生理（心臟发育、网状红血球成熟和心肌血管生成）和病理生理过程（包括缺血/再灌注（IR）损伤、动脉粥样硬化和心臟重塑）之间的关联。缺氧和发炎等压力条件可以调节生物外泌体含量和目标细胞，有助于改善或损害心臟功能。基于外泌体的 miRNA 和蛋白质在体液中的整合能够全面分析这些成分在心血管疾病中的潜在生物标记作用。因此，外泌体生物标记的使用正在成为诊断CVD的新方法。

阻碍北美心臟标记市场的因素

公司可以针对特定应用向 FDA 生物标记资格计画提交心臟标记监管资格申请。只有合格的标记物才可以用于多个药物开发项目，而不需要药物评估与研究中心（CDER）的批准来重新确认标记物的适用性。

心臟标记广泛应用于流行病学研究，以完成 CVD 多个阶段的调查。该过程需要更仔细地处理和储存有价值的生物样本以获得详细资讯。需要精确的品质控制措施来确保这些样本在适当的储存条件下处理，以避免资料遗失。心臟标记研究取决于样本的完整性以及收集、处理和储存的方式，因为这些研究中使用存檔样本。处理、标籤、加工、等分、储存和运输可能会影响研究结果。样品必须放置在干冰上并在当天发货。如果该过程执行不当，可能会影响样品的质量，从而影响结果。因此，美国 FDA 制定的严格验证协议以及与样本采集和储存相关的技术问题阻碍了北美心臟标记市场的成长。

根据疾病，北美心臟标记市场分为HIV检测、流感检测、性传染病检测、C型肝炎病毒检测、热带疾病检测、呼吸道感染检测、医院获得性感染、链球菌等。根据分子诊断，市场进一步分为聚合酶连锁反应（PCR）、等温核酸扩增技术（INAAT）等。 2023 年，呼吸道感染检测领域占据最大的市场。

根据产品类型，北美心臟标记市场分为试剂和试剂盒以及分析仪。分析仪细分市场在 2023 年占据更大份额。

根据生物标记类型，北美心臟标记市场分为肌钙蛋白、肌酸激酶-MB、肌红蛋白、B型利尿钠肽等。肌钙蛋白细分市场在 2023 年占据最大的市场份额，预计 2023-2031 年市场复合年增长率最高。

依适应症，市场分为充血性心臟衰竭、心肌梗塞、急性冠状动脉综合症等。充血性心臟衰竭细分市场在 2023 年占据最大市场份额。

就最终用户而言，北美心臟标记市场分为医院、诊断实验室、即时检测设施等。 2023 年，医院细分市场占据最大的市场份额。

北美传染病床边分子检测市场：区域概览

发达的医疗保健系统以及用于诊断和预测疾病的心臟标记的高度接受度。不断增长的老年人口需要生物标记测试来检测急性心肌梗塞等疾病，从而推动了对测试产品的需求。该地区 Quidel 公司和丹纳赫公司等主要参与者的存在是促进该市场成长的另一个因素。根据世界卫生组织(WHO) 统计，约7,700 万18 岁以上成年人患有2 型糖尿病，其中2,500 万人处于糖尿病前期，增加了心血管疾病(CVD) 的可能性，并给医疗保健系统带来了额外压力。此外，该地区市场参与者采取越来越多的策略来开发创新的心臟生物标记测试，预计将有助于该地区的市场成长。

在准备北美心臟标记市场报告时提到的一些主要一手和二手来源包括世界银行数据、国家卫生服务部 (NHS)、美国卫生与公众服务部 (HHS) 和世界卫生组织 (世界银行) 数据。卫生组织）。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解

第 3 章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第 4 章：北美心臟标记物市场格局

  • 概述
  • PEST分析

第 5 章：北美心臟标记市场 - 主要市场动态

  • 北美心臟标记物市场 - 主要市场动态
  • 市场驱动因素
    • 心血管疾病盛行率上升
    • 对即时心臟检测套件的需求激增
  • 市场限制
    • 与样品采集和储存相关的严格验证和技术问题
  • 市场机会
    • 心血管领域投资
  • 未来的趋势
    • 使用外泌体作为 CVD 生物标记的持续研究
  • 影响分析

第 6 章：北美心臟标记物市场分析

  • 北美心臟标记物市场收入，2021-2031

第 7 章：北美心臟标记市场分析 - 按产品类型

  • 分析仪
  • 试剂和试剂盒

第 8 章：北美心臟标记市场分析 - 按生物标记类型

  • 肌钙蛋白
  • 肌酸激酶-MB
  • 肌红蛋白
  • B型利钠肽
  • 其他的

第 9 章：北美心臟标记市场分析 - 按适应症

  • 充血性心臟衰竭
  • 心肌梗塞
  • 急性冠状动脉综合症
  • 其他的

第 10 章：北美心臟标记物市场分析 - 按最终用户

  • 医院
  • 诊断实验室
  • 即时侦测设施
  • 其他的

第 11 章：北美心臟标记市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 12 章：产业格局

  • 概述
  • 近期发展策略
    • 概述

第 13 章：心臟标记物市场-产业格局

  • 概述
  • 有机成长策略
    • 概述

第 14 章：公司简介

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc
  • Beckman Coulter Inc
  • Bio-Rad Laboratories Inc
  • Creative Diagnostics
  • Diazyme Laboratories, Inc.
  • bioMerieux SA
  • HyTest Ltd.
  • QuidelOrtho Corp

第 15 章：附录

Product Code: TIPRE00039162

The global North America cardiac marker market is expected to reach US$ 2.87 billion by 2031 from US$ 1.17 billion in 2023. The market is estimated to grow with a CAGR of 11.8% from 2023 to 2031.

The North America cardiac marker market forecast presented in this report can help stakeholders in this marketplace plan their growth strategies. The rising prevalence of cardiovascular diseases and a surge in the demand for point-of-care cardiac testing kits are the key factors propelling the North America cardiac marker market growth.

Ongoing Research in Use of Exosomes as CVD Biomarkers

Hypoxia significantly affects exosome cargo and produces various proteins and miRNAs that indicate angiogenesis, growth, and progression for CVD through different signaling pathways. Exosomes has gathered the attention of researchers because they are relevant to intercellular communication under both physiological and pathological conditions. The upregulated exosome miRNAs miR-133a, miR-208a, miR-1, miR-499-5p, and miR-30a have been designated for the timely diagnosis of acute myocardial infarction (AMI). Further, derived exosomes namely, miR-192, miR-146a, miR-194, and miR-92b-5p are considered as potential biomarkers for HF.

  • Table 1. Exosomes as CVD Biomarkers

Biomarker Disease Function

miRNA-126, miRNA-223, and miRNA-320b Acute myocardial infarction Platelet activation and thrombus formation, endothelial damage, myocardial apoptosis, and fibroblast proliferation

miRNA-1, miRNA-21a/b, and miRNA-29b Acute myocardial infraction Myocardial apoptosis, fibroblast proliferation, and cardiac hypertrophy

miRNA-208a Acute myocardial infarction Cardiac hypertrophy and electrical conduction

miRNA-499 Acute myocardial infarction Myocardial apoptosis

miRNA-486 Acute myocardial infarction Myocardial apoptosis (protective)

miRNA-223-5p Acute myocardial infarction, atherosclerosis, and heart failure Cell proliferation, migration, apoptosis, and polarization; cardiomyocyte hypertrophy; and electrical conduction

miRNA-941 Acute coronary syndrome Cell proliferation and inflammation

miRNA-216a and miRNA-451 Coronary artery disease Endothelial damage and monocyte recruitment

miRNA-223-3p, miRNA-122-5p, and miRNA-93-5p Coronary artery disease Inflammation, migration and apoptosis, cardiomyocyte hypertrophy, electrical conduction, and cardiomyocyte apoptosis

miRNA-142-3p, miRNA-17-5p, and miRNA-126 Acute myocardial infarction and coronary artery disease Inflammation; cardiomyocyte hypertrophy; and cell proliferation, migration, and apoptosis

miRNA-133a Coronary artery disease Cell proliferation and differentiation, cardiac hypertrophy, and electrical conduction (arrhythmia)

Serpin G1, Serpin F2, and Cystatin C CD14 Heart failure and acute coronary syndrome Inflammation, decrease in kidney function, decrease in fibrinolysis, and thrombotic process

Source: Allen Press

In coronary artery disease (CAD) patients, upregulated exosome proteins-including fibrinogen beta/gamma chain, alpha-1-antichymotrypsin, and inter-alpha-trypsin inhibitor heavy chain-were evaluated as putative protein biomarkers. The function of exosomes in CVD pathogenesis through diverse intercellular communication mechanisms is gaining significant recognition. Several studies conducted in recent years have generated evidence supporting the association of exosomes with normal physiology (cardiac development, reticulocyte maturation, and myocardial angiogenesis) and pathophysiological processes, including ischemia/reperfusion (IR) injury, atherosclerosis, and cardiac remodeling. Stressful conditions such as hypoxia and inflammation can modulate biological exosome content and target cells, thereby contributing to improving or impairing cardiac function. The integration of exosome-based miRNAs and proteins in body fluids enables a comprehensive analysis of the potential biomarker role of these components in cardiovascular diseases. Therefore, the use of exosome biomarkers is emerging as a new approach for the diagnosis of CVDs.

Factor Hampering North American Cardiac Marker Market

Companies can submit an application for regulatory qualification for a cardiac marker to the FDA Biomarker Qualification Program for a specific application. Only the qualified marker can be used in multiple drug development programs without the need for the Center for Drug Evaluation and Research (CDER) approval to reconfirm the suitability of the markers.

Cardiac markers are widely used in epidemiological studies for completing the investigation of numerous stages of CVD. The process requires more careful handling and storage of valuable biological samples to obtain detailed information. Precise quality control measures are required to ensure that these samples are handled in appropriate storage conditions to avoid data loss. Cardiac marker studies depend on the integrity of samples and the manner of collection, processing, and storage, as archived samples are used in these studies. Handling, labeling, processing, aliquoting, storage, and transportation may affect study results. The sample must be placed on dry ice and shipped the same day. If the process is not carried out properly, it can impact the quality of the sample, subsequently hampering the outcomes. Therefore, strict validation protocols established by the US FDA and technical issues associated with sample collection and storage hamper the growth of the North America cardiac markers market.

Based on disease, the North America cardiac marker market is divided into HIV testing, influenza testing, sexually transmitted diseases testing, hepatitis C virus testing, tropical diseases testing, respiratory infection testing, hospital-acquired infections, strep, and others. The market is further divided on the basis of molecular diagnostics into polymerase chain reactions (PCR), isothermal nucleic acid amplification technology (INAAT), and others. The respiratory infection testing segment held the largest market share in 2023.

Based on product type, the North America cardiac markers market is segmented into reagents and kits, and analyzers. The analyzers segment held a larger share in 2023. The reagents and kits segment is expected to register a higher CAGR during 2023-2031.

Based on biomarker type, the North America cardiac markers market is divided into troponin, creatine kinase-MB, myoglobin, B-type natriuretic peptide, and others. The troponin segment held the largest market share in 2023 and is estimated to register the highest CAGR in the market during 2023-2031.

By indication, the market is segmented into congestive heart failure, myocardial infraction, acute coronary syndrome, and others. The congestive heart failure segment held the largest share of the market in 2023. The acute coronary syndrome segment is estimated to register the highest CAGR during 2023-2031.

In terms of end user, the North America cardiac markers market is divided into hospitals, diagnostic laboratories, point-of-care testing facilities, and others. The hospitals segment held the largest market share in 2023. The diagnostic laboratories segment is estimated to register the highest CAGR in the market during 2023-2031.

North America Point-Of-Care Molecular Testing for Infectious Diseases Market: Regional Overview

The the developed healthcare system and the high acceptance of cardiac markers for diagnosing and predicting diseases. The growing geriatric population needs biomarker testing for detecting conditions such as acute myocardial infarction, thereby driving demand for testing products. The existence of key players such as Quidel Corporation and Danaher Corporation in the region is another factor contributing to the growth of this market. According to the World Health Organization (WHO), ~77 million adults over the age of 18 have type 2 diabetes, including 25 million prediabetes, which increases the possibility of cardiovascular diseases (CVDs) and puts additional pressure on the healthcare system. Furthermore, increasing strategies adopted by market players in this region to develop innovative cardiac biomarker tests are expected to contribute to the market growth in this region.

A few of the major primary and secondary sources referred to while preparing the report on the North America cardiac marker market are the World Bank Data, National Health Service (NHS), US Department of Health and Human Services (HHS), and WHO (World Health Organization).

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Cardiac Marker Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Cardiac Marker Market - Key Market Dynamics

  • 5.1 North America Cardiac Marker Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Cardiovascular Diseases
    • 5.2.2 Surge in Demand for Point-of-Care Cardiac Testing Kits
  • 5.3 Market Restraints
    • 5.3.1 Strict Validation and Technical Issues Related to Sample Collection and Storage
  • 5.4 Market Opportunities
    • 5.4.1 Investments in Cardiovascular Sector
  • 5.5 Future Trends
    • 5.5.1 Ongoing Research in Use of Exosomes as CVD Biomarkers
  • 5.6 Impact analysis

6. North America Cardiac Marker Market Analysis

  • 6.1 North America Cardiac Marker Market Revenue (US$ Million), 2021-2031

7. North America Cardiac Marker Market Analysis - by Product Type

  • 7.1 Analyzers
    • 7.1.1 Overview
    • 7.1.2 Analyzers: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Reagents and Kits
    • 7.2.1 Overview
    • 7.2.2 Reagents and Kits: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Cardiac Marker Market Analysis - by Biomarker Type

  • 8.1 Troponin
    • 8.1.1 Overview
    • 8.1.2 Troponin: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Creatine Kinase-MB
    • 8.2.1 Overview
    • 8.2.2 Creatine Kinase-MB: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Myoglobin
    • 8.3.1 Overview
    • 8.3.2 Myoglobin: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 B-Type Natriuretic Peptide
    • 8.4.1 Overview
    • 8.4.2 B-Type Natriuretic Peptide: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Cardiac Marker Market Analysis - by Indication

  • 9.1 Congestive Heart Failure
    • 9.1.1 Overview
    • 9.1.2 Congestive Heart Failure: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Myocardial Infraction
    • 9.2.1 Overview
    • 9.2.2 Myocardial Infraction: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.3 Acute Coronary Syndrome
    • 9.3.1 Overview
    • 9.3.2 Acute Coronary Syndrome: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.4 Others
    • 9.4.1 Overview
    • 9.4.2 Others: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Cardiac Marker Market Analysis - by End User

  • 10.1 Hospitals
    • 10.1.1 Overview
    • 10.1.2 Hospitals: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Diagnostic Laboratories
    • 10.2.1 Overview
    • 10.2.2 Diagnostic Laboratories: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Point-of-Care Testing Facilities
    • 10.3.1 Overview
    • 10.3.2 Point-of-Care Testing Facilities: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.4 Others
    • 10.4.1 Overview
    • 10.4.2 Others: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Cardiac Marker Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Cardiac Marker Market Breakdown by Countries
    • 11.1.2 North America Cardiac Marker Market Revenue and Forecast and Analysis - by Country
      • 11.1.2.1 United States: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.1 United States: North America Cardiac Marker Market Breakdown by Product Type
        • 11.1.2.1.2 United States: North America Cardiac Marker Market Breakdown by Biomarker Type
        • 11.1.2.1.3 United States: North America Cardiac Marker Market Breakdown by Indication
        • 11.1.2.1.4 United States: North America Cardiac Marker Market Breakdown by End User
      • 11.1.2.2 Canada: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.1 Canada: North America Cardiac Marker Market Breakdown by Product Type
        • 11.1.2.2.2 Canada: North America Cardiac Marker Market Breakdown by Biomarker Type
        • 11.1.2.2.3 Canada: North America Cardiac Marker Market Breakdown by Indication
        • 11.1.2.2.4 Canada: North America Cardiac Marker Market Breakdown by End User
      • 11.1.2.3 Mexico: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.1 Mexico: North America Cardiac Marker Market Breakdown by Product Type
        • 11.1.2.3.2 Mexico: North America Cardiac Marker Market Breakdown by Biomarker Type
        • 11.1.2.3.3 Mexico: North America Cardiac Marker Market Breakdown by Indication
        • 11.1.2.3.4 Mexico: North America Cardiac Marker Market Breakdown by End User

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Recent Development Strategies
    • 12.2.1 Overview

13. Cardiac Marker Market-Industry Landscape

  • 13.1 Overview
  • 13.2 Organic Growth Strategies
    • 13.2.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 F. Hoffmann-La Roche Ltd
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Thermo Fisher Scientific Inc
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 Beckman Coulter Inc
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 Bio-Rad Laboratories Inc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Creative Diagnostics
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Diazyme Laboratories, Inc.
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 bioMerieux SA
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 HyTest Ltd.
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 QuidelOrtho Corp
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners
  • 15.2 Glossary of Terms

List Of Tables

  • Table 1. North America Cardiac Marker Market Segmentation
  • Table 2. Available POC Products in the US
  • Table 3. Exosomes as CVD Biomarkers
  • Table 4. United States: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 5. United States: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Biomarker Type
  • Table 6. United States: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 7. United States: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 8. Canada: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 9. Canada: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Biomarker Type
  • Table 10. Canada: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 11. Canada: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 12. Mexico: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Product Type
  • Table 13. Mexico: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Biomarker Type
  • Table 14. Mexico: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. Mexico: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million) - by End User
  • Table 16. Recent Development Activities in the Cardiac Marker Market
  • Table 17. Recent Organic Growth Strategies in the Cardiac Marker Market
  • Table 18. Glossary of Terms, North America Cardiac Marker Market

List Of Figures

  • Figure 1. North America Cardiac Marker Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. North America Cardiac Marker Market Revenue (US$ Million), 2021-2031
  • Figure 5. North America Cardiac Marker Market Share (%) - by Product Type, 2023 and 2031
  • Figure 6. Analyzers: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Reagents and Kits: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. North America Cardiac Marker Market Share (%) - by Biomarker Type, 2023 and 2031
  • Figure 9. Troponin: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Creatine Kinase-MB: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Myoglobin: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. B-Type Natriuretic Peptide: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Others: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. North America Cardiac Marker Market Share (%) - by Indication, 2023 and 2031
  • Figure 15. Congestive Heart Failure: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Myocardial Infraction: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Acute Coronary Syndrome: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Others: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. North America Cardiac Marker Market Share (%) - by End User, 2023 and 2031
  • Figure 20. Hospitals: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 21. Diagnostic Laboratories: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Point-of-Care Testing Facilities: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. Others: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. North America Cardiac Marker Market Breakdown by Key Countries, 2023 and 2031 (%)
  • Figure 25. United States: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Canada: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Mexico: North America Cardiac Marker Market - Revenue and Forecast to 2031 (US$ Million)